Bevacizumab's Value in Recurrent Ovarian Cancer
Watch
Approaching Platinum-Refractory Recurrent Ovarian Cancer
Selecting Optimal Upfront Therapy for Ovarian Cancer
Considerations Regarding Newly Diagnosed Ovarian Cancer
Approaching a Case of Stage 3C Ovarian Cancer
A Case of Recurrent Ovarian Cancer
Ovarian Cancer: Looking Toward Later-Line Therapy
Managing PARP Inhibitor Toxicities in Ovarian Cancer
Rucaparib in Recurrent Ovarian Cancer: ARIEL3 Trial
Optimizing Therapy in Recurrent Ovarian Cancer
Frontline Bevacizumab Strategies in Ovarian Cancer
Approaching a Case of Advanced Serous Ovarian Cancer
A Case of Advanced Serous Ovarian Cancer
Recurrent Ovarian Cancer: Third-Line Therapy and Beyond
Defining Rucaparib's Value in Recurrent Ovarian Cancer
Recurrent Ovarian Cancer: Selecting Second-Line Therapy
Approaching Frontline Therapy Options for Ovarian Cancer
A Case of Platinum-Sensitive Epithelial Ovarian Cancer
CLL: Combination Therapies and Future Outlook
Therapeutic Approach for CLL Progression
CLL: Rationale for Ibrutinib and Chemotherapy
Treatment Options for CLL
Risk Stratifying a Case of CLL
Treating Chronic Lymphocytic Leukemia in Elderly Patients
Case 4: Maintenance Strategies in CLL
Case 4: iFCR in Untreated CLL
Case 4: iFCG in Untreated CLL
Case 4: A Young, Fit Patient With MRD-Positive CLL After Immunochemotherapy
Case 3: Therapeutic Approaches for Richter Transformation
